People In Brief
This article was originally published in The Rose Sheet
Executive SummaryP&G Brings On U.S. Sustainability Experts
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.